The Boston Scientific Corp (BSX) has seen substantial activity recently with an array of institutional investors either increasing or decreasing their stakes in the company. Raymond James raised the price target to $119 from $101, demonstrating their bullish stance. Oak Harvest Investment Services, Mediolanum International Funds Ltd, Caprock Group LLC, Blue Trust Inc. and KBC Group NV significantly increased their shares in BSX; conversely, notable reductions were made by Factory Mutual Insurance, Perigon Wealth Management, and Swedbank AB. Predictions for Q4 earnings are buzzing, with many analysts expecting strong results. The acquisition of both Cortex Inc. and Intera Oncology Inc. by Boston Scientific is expected to strengthen the company's portfolio. However, despite the stock's impressive rally, some investors express concern due to the ambiguous financial health of the company. Overall, the bullish sentiments seem to outweigh bearish concerns currently given the strong recent performance of the stock and positive business decisions made by the company.
Boston Scientific Corp BSX News Analytics from Wed, 24 Apr 2024 07:00:00 GMT to Sat, 01 Feb 2025 17:30:50 GMT - Rating 7 - Innovation 4 - Information 6 - Rumor -2
